65
Participants
Start Date
December 7, 2020
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
Placebo
Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
Mirabegron
Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
Mirabegron 50 MG
Participants will take one pill (50mg Mirabegron) daily between visit 2 and visit 3
Mirabegron 100 mg
participants will be given 6 weeks of mirabegron (25 mg) and will take 1 pill once per day for 4-6 weeks. Next participants will be given 6 weeks of mirabegron (50 mg) and take 1 pill once per day for 4-6 weeks. Last participants will be given 6 weeks of mirabegron (100 mg) and take 1 pill once per day for 4-6 weeks.
RECRUITING
University of Kentucky, Lexington
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Philip Kern
OTHER